ReviewDiabetologia2012
Obstacles on the way to the clinical visualisation of beta cells: looking for the Aeneas of molecular imaging to navigate between Scylla and Charybdis.
Review in Diabetologia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Bibliometric analysis of research on the utilization of nanotechnology in diabetes mellitus and its complications.Nanomedicine (London, England) · 2024Article
- Pancreatic beta-cell mass and function and therapeutic implications of using antidiabetic medications in type 2 diabetes.Journal of diabetes investigation · 2024Review
- Cross-sectional imaging of the pancreas in diabetes.Abdominal radiology (New York) · 2024Review
- New Insights and Potential Therapeutic Interventions in Metabolic Diseases.International journal of molecular sciences · 2023Review
- Nanobodies for Medical Imaging: About Ready for Prime Time?Biomolecules · 2021Review
- Non-invasive Beta-cell Imaging: Visualization, Quantification, and Beyond.Frontiers in endocrinology · 2021Review
- Beta Cell Imaging-From Pre-Clinical Validation to First in Man Testing.International journal of molecular sciences · 2020Review
- Nanomedicine-Based Strategies for Diabetes: Diagnostics, Monitoring, and Treatment.Trends in endocrinology and metabolism: TEM · 2020Review
- A nanobody-based nuclear imaging tracer targeting dipeptidyl peptidase 6 to determine the mass of human beta cell grafts in mice.Diabetologia · 2020Article
- PET/MRI enables simultaneousTheranostics · 2020Article
- Molecular imaging of β-cells: diabetes and beyond.Advanced drug delivery reviews · 2019Review
- Imaging of Human Insulin Secreting Cells with Gd-DOTA-P88, a Paramagnetic Contrast Agent Targeting the Beta Cell Biomarker FXYD2γa.Molecules (Basel, Switzerland) · 2018Article
- Optical clearing of the pancreas for visualization of mature β-cells and vessels in mice.Islets · 2018Article
- Improved Labeling of Pancreatic Islets Using Cationic Magnetoliposomes.Journal of personalized medicine · 2018Article
- Enhanced Specific Activity by Multichelation of Exendin-3 Leads To Improved Image Quality and In Vivo Beta Cell Imaging.Molecular pharmaceutics · 2018Article
- A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells.Scientific reports · 2017Article
- Biochemical profiling of diabetes disease progression by multivariate vibrational microspectroscopy of the pancreas.Scientific reports · 2017Article
- Multifunctional in vivo imaging of pancreatic islets during diabetes development.Journal of cell science · 2016Article
- Combined Optical Coherence and Fluorescence Microscopy to assess dynamics and specificity of pancreatic beta-cell tracers.Scientific reports · 2015Article
- Targeting GLP-1 receptors for repeated magnetic resonance imaging differentiates graded losses of pancreatic beta cells in mice.Diabetologia · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For more than a decade, researchers have been trying to develop non-invasive imaging techniques for the in vivo measurement of viable pancreatic beta cells. However, in spite of intense research efforts, only one tracer for positron emission tomography (PET) imaging is currently under clinical evaluation. To many diabetologists it may remain unclear why the imaging world struggles to develop an effective method for non-invasive beta cell imaging (BCI), which could be useful for both research and clinical purposes. Here, we provide a concise overview of the obstacles and challenges encountered on the way to such BCI, in both native and transplanted islets. We discuss the major difficulties posed by the anatomical and cell biological features of pancreatic islets, as well as the chemical and physical limits of the main imaging modalities, with special focus on PET, SPECT and MRI. We conclude by indicating new avenues for future research in the field, based on several remarkable recent results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.